Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection

Archives of Pharmacal Research

Volumn 30, Issue 6, 2007, Pages 778-784

  Jong, Soo Woo ^a  

^a Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

Granisetron; LC MS; Nasal administration

Indexed keywords

EID: 34347389038     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02977642     Document Type: Article

References (15)

1. Bjerre, C., Björk, E., and Camber, O., Bioavailability of the sedative propiomazine after nasal administration in rats. Int. J. Pharm., 144, 217-224 (1996).
2. Blum, R. A., Majumdar, A., McCrea, J., Busillo, J., Orlowski, L. H., Panebianco, D., Hesney, M., Petty, K. J., Goldberg, M. R., Murphy, M. G., Gottesdiener, K. M., Hustad, C. M., Lates, C., Kraft, W. K., Van Buren, S., Waldman, S. A., and Greenberg, H. E., Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin. Ther., 25, 1407-1419 (2003).
3. Boppana, V. K., Simultaneous determination of granisetron and its 7-hydroxy metabolite in human plasma by reversed-phase high-performance liquid chromatography utilizing fluorescence and electrochemical detection. J. Chromatogr. A., 692, 195-202 (1995).
4. Boppana, V. K., Miller-Stein, C., and Schaefer, W. H., Direct plasma liquid chromatographic-tandem mass spectrometric analysis of granisetron and its 7-hydroxy metabolite utilizing internal surface reversed-phase guard columns and automated column switching devices. J. Chromatogr. B., 678, 227-236 (1996).
5. Bressolle, F., Bromet-Petit, M., and Audran, M., Validation of liquid chromatographic and gas chromatographic methods Applications to pharmacokinetics. J. Chromatogr. B., 686, 3-10 (1996).
6. Carmichael, J., Cantwell, B. M., Edwards, C. M., Zussman, B. D., Thompson, S., Rapeport, W. G., and Harris, A. L., A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with antiemetic response. Cancer Chemother. Pharmacol., 24, 45-49 (1989).
7. Huang, C.-T., Chen, K.-C., Chen, C.-F., and Tsai, T.-H., Simultaneous measurement of blood and brain microdialysates of granisetron in rat by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B., 716, 251-255 (1998).
8. Hussain, A. A., Dakkuri, A., and Itoh, S., Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother. Pharmacol., 45, 432-434 (2000).
9. Hussain, A. A., Hirai, S., and Bawarshi, R., Nasal absorption of propranolol from different dosage forms by rats and dogs. J. Pharm. Sci., 69, 1411-1413 (1980).
10. International Conference on Harmonization, Note for Guidance on Validation of Analytical Procedures: Methodology, Committee for Proprietary Medical Products, CPMP/ICH/281/95, Approval 18 December 1996.
11. Kudoh, S., Sato T., Okada, H., Kumakura, H., and Nakamura, H., Simultaneous determination of granisetron and 7-hydroxygranisetron in human plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B., 660, 205-210 (1994).
12. Physicians' Desk Reference, 59th ed (2005) Medical Economics, Montvale, New Jersey, pp. 2901-2903
13. 3 receptor antagonism by BRL 43694 (granisetron). Eur. J. Pharmacol., 159, 113-124 (1989).
14. United States Pharmacopoeia 23, Section 1225, Validation of Compendial Methods, United States Pharmacopoeia Convention, Inc., Rockville, MD, 1995.
15. Upward, J. W., Arnold, B. D., Link, C., Pierce, D. M., Allen, A., and Tasker, T. C., The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur. J. Cancer, 26, S12-S15 (1990).